Contineum Therapeutics (CTNM) Shares Outstanding (2023 - 2026)

Contineum Therapeutics' Shares Outstanding (Entity) history runs 4 years deep, the most recent figure standing at $37.6 million for Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 45.11% year-over-year to $37.6 million; the TTM figure through Jun 2026 stood at $37.6 million (up 45.11% YoY), while the FY2025 annual figure was $27.7 million, up 43.14% from the prior year.
• Shares Outstanding (Entity) for Q2 2026 stood at $37.6 million, up from $37.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $37.6 million in Q2 2026, with the low at $2.3 million in Q1 2023.
• The 4-year median for Shares Outstanding (Entity) is $25.7 million (2024), against an average of $20.0 million.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) soared 1020.66% in 2024, then climbed 0.76% in 2025.
• Contineum Therapeutics' Shares Outstanding (Entity) stood at $2.3 million in 2023, then jumped by 736.66% to $19.4 million in 2024, then jumped by 43.14% to $27.7 million in 2025, then surged by 35.78% to $37.6 million in 2026.
• Business Quant data shows CTNM's Shares Outstanding (Entity) at $37.6 million in Q2 2026, $37.4 million in Q1 2026, and $27.7 million in Q4 2025.